• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    William Blair initiated coverage on Tenax Therapeutics

    9/30/24 7:51:49 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TENX alert in real time by email
    William Blair initiated coverage of Tenax Therapeutics with a rating of Outperform
    Get the next $TENX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TENX

    DatePrice TargetRatingAnalyst
    10/24/2024$16.00Outperform
    Leerink Partners
    10/14/2024$16.00Buy
    Guggenheim
    9/30/2024Outperform
    William Blair
    More analyst ratings

    $TENX
    Financials

    Live finance-specific insights

    See more
    • Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

      Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. "Having completed the merger with PHPrecisionMed Inc., we now have product development programs in group one and group two pulmonary hypertension patients," stated Anthony DiTonno, Chief Executive Officer of Tenax, "which represent more than 70% of the overall market. "We have begun the open label transition study using the oral formulation of Levosimendan, which was recently acq

      5/17/21 5:15:00 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

      MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax’s pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase i

      1/19/21 7:45:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Leadership Updates

    Live Leadership Updates

    See more
    • Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

      CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Ms. Andor will lead the Company's expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). "We are

      1/22/25 8:00:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board

      CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company's PH-HFpEF Scientific Advisory Board (SAB). "We are thrilled to welcome Dr. Butler to our Scientific Advisory Board," said Stuart Rich, M.D., Chief Medical Officer of Tenax Therapeutics. "Javed is regarded as one of the most eminent clinical trialists in cardiovascular medicine, and he joins three highly distinguished cardiovascular lead

      11/17/23 8:30:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Tenax Therapeutics with a new price target

      Leerink Partners initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $16.00

      10/24/24 6:39:21 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Tenax Therapeutics with a new price target

      Guggenheim initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $16.00

      10/14/24 7:43:13 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Tenax Therapeutics

      William Blair initiated coverage of Tenax Therapeutics with a rating of Outperform

      9/30/24 7:51:49 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TENX
    SEC Filings

    See more
    • SEC Form SC 13G filed by Tenax Therapeutics Inc.

      SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/14/24 7:14:21 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

      SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/14/24 12:21:05 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

      SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/13/24 5:35:29 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Tenax Therapeutics Inc.

      DEFA14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/25/25 7:45:16 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Tenax Therapeutics Inc.

      DEF 14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/25/25 7:42:43 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Tenax Therapeutics Inc.

      EFFECT - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/24/25 12:15:09 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by no longer 10% owner Dellora Investments Lp

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      3/12/25 5:26:30 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dellora Investments Lp claimed ownership of 351,071 shares (SEC Form 3)

      3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      1/10/25 4:27:18 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Rich Stuart

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      12/12/24 8:09:56 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

      CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025. Details of presentation: Format: Corporate Presentation Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer, Doug Randall, Chief Business Officer Date and Time: April 7, 2025, at 3:45 p.m. ET The live and archived webcast of

      3/31/25 8:00:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3 LEVEL Study Expansion Increases Statistical Power; Enrollment Completion Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies,

      3/25/25 4:05:00 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Announces $25 Million Private Placement

      CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private placement expenses. The private placement will be for an aggregate of 378,346 shares of the Company's common stock and pre-funded warrants to purchase an aggrega

      3/5/25 8:47:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Proehl Gerald T bought 1,666 shares, increasing direct ownership by 166,600% to 1,667 units (SEC Form 4)

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      8/8/24 7:43:25 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Davidson Michael H. bought 2,500 shares, increasing direct ownership by 656% to 2,881 units (SEC Form 4)

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      8/8/24 7:42:23 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care